Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients (MG600)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01151683 |
|
Recruitment Status :
Completed
First Posted : June 28, 2010
Last Update Posted : January 7, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Introduction: Magnesium has been the target for many experimental and clinical studies due to the negative correlation between its serum and intracellular levels and the prevalence of hypertension and other cardiovascular diseases.
Objective: To evaluate the effects of magnesium supplementation in hypertensive patients who are under diuretic treatment, including correlation of clinical and nutritional parameters with structural and functional aspects of the macrocirculation.
Methods: A prospective, randomized, double blind, placebo controlled study will be performed in hypertensive patients, aged between 40 and 65 years-old, in regular use of thiazidic diuretic as antihypertensive monotherapy,. The patients will be divided in two main groups according to supplementation with placebo or magnesium chelate 300mg twice a day (total of 600mg magnesium element per day). Before and after 3 and 6 months of supplementation, the patients will be submitted to clinical and nutritional evaluation, biochemical analysis, including intracellular magnesium measurement, and study of the macrocirculation with ambulatory blood pressure monitoring, analysis of flow-mediated dilation of brachial artery, measurement of carotid intima-media thickness, and carotid-femoral and carotid-radial pulse wave velocity to estimate central and peripheral arterial stiffness.
Analysis: Data will be expressed as mean±epm. Statistical analysis will be performed using software Prism® (GraphPad, version 5.0). Continuous variables in each group will be compared using "t test", and P<0.05 will be considered statistically significant.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hypertension Endothelial Dysfunction | Dietary Supplement: magnesium Dietary Supplement: placebo | Phase 4 |
The main objective of this study is to evaluate whether magnesium supplementation is associated with improved blood pressure control and whether it has beneficial effects on the vascular structure and function in non-diabetic hypertensive patients who are receiving r diuretic therapy.
Patients will be evaluated in a prospective, randomized, double-blind study and will be admitted to the study if they reach all the inclusion criteria and no exclusion criteria.
In this study, magnesium chelate was chosen because of its better absorption rate. The dosages are different in many protocols but in this project the patients will receive 600 mg of magnesium element daily divided in 300 mg twice a day. The patients will be divided in two main groups according to supplementation with placebo or magnesium chelate 300mg twice a day (total of 600mg magnesium element per day). Before and after 3 and 6 months of supplementation, the patients will be submitted to clinical and nutritional evaluation, biochemical analysis, including intracellular magnesium measurement, and study of the macrocirculation with ambulatory blood pressure monitoring, analysis of flow-mediated dilation of brachial artery, measurement of carotid intima-media thickness, and carotid-femoral and carotid-radial pulse wave velocity to estimate central and peripheral arterial stiffness.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 52 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Supportive Care |
| Official Title: | Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients |
| Study Start Date : | March 2010 |
| Actual Primary Completion Date : | November 2012 |
| Actual Study Completion Date : | November 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Magnesium
Magnesium chelate 600 mg per day
|
Dietary Supplement: magnesium
Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
Other Name: Mg supplement |
|
Placebo Comparator: Placebo
Placebo 4 capsules per day
|
Dietary Supplement: placebo
Two capsules of placebo per oral twice a day
Other Name: Inactive component |
- Improvement of vascular function [ Time Frame: six months ]
- Improvement of vascular structure and blood pressure [ Time Frame: six months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women aged between 40 and 65 years-old
-
Hypertension with mild blood pressure elevation:
- Systolic BP between 140 and 159mmHg AND/OR
- Diastolic BP between 90 and 99 mmHg
- Antihypertensive monotherapy with daily use of thiazidic diuretic, at least in the last 30 days
- Signature of the Informed Consent by the patient or his legal representative
Exclusion Criteria:
- Evidences for secondary hypertension
- Hypertension in stage 2, SBP ≥ 160mmHg and/or DBP ≥ 100mmHg, before the beginning of supplementation
- Blood pressure > 180 x 100 mmHg in any phase of the study
- Body mass index > 35 kg/m2
- Diabetes Mellitus
- Renal disease presenting glomerular filtration rate < 60ml/min
- Coronary artery disease clinically evident with previous episode of myocardial infarction and/or myocardial revascularization
- Clinical signs of heart failure
- History of stroke
- Any condition, disease or therapy that, under investigator's opinion, may influence objectives, results, or put in risk the safety of the patients.
- Pregnancy
- Patients should not be taking any mineral or vitamin supplements
- Gastrointestinal conditions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01151683
| Brazil | |
| Department of Clinical Medicine, State University of Rio de Janeiro | |
| Rio de Janeiro, RJ, Brazil, 20551030 | |
| Principal Investigator: | Mario F Neves, MD, PhD | State University of Rio de Janeiro |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Mario Fritsch Neves, Full Professor, Rio de Janeiro State University |
| ClinicalTrials.gov Identifier: | NCT01151683 History of Changes |
| Other Study ID Numbers: |
MG600 |
| First Posted: | June 28, 2010 Key Record Dates |
| Last Update Posted: | January 7, 2013 |
| Last Verified: | January 2013 |
Keywords provided by Mario Fritsch Neves, Rio de Janeiro State University:
|
hypertension endothelial dysfunction |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases |